Results of Placing

Summary by AI BETAClose X

Arecor Therapeutics plc has successfully conditionally placed 7,352,941 new ordinary shares at 68 pence per share, raising gross proceeds of approximately £5.0 million. This capital injection will strengthen the company's balance sheet, extend its cash runway to December 2027, and fund critical insulin development activities. The new shares will rank pari passu with existing ordinary shares, and admission to trading on AIM is expected by October 6, 2026.

Disclaimer*

UK 100

Latest directors dealings